Mason Wakley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mason Wakley has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- David House
Crick-GSK Biomedical LinkLabs, GSK, Gunnels Wood Road, Stevenage, Hertfordshire, UK
3 shared publications - George S. Biggs
Crick-GSK Biomedical LinkLabs, GSK, Gunnels Wood Road, Stevenage, Hertfordshire, UK
3 shared publications - Harry Wilders
Crick-GSK Biomedical LinkLabs, GSK, Gunnels Wood Road, Stevenage, Hertfordshire, UK
3 shared publications - Jacob T. Bush
Chemical Biology, GlaxoSmithKline, Gunnels Wood Rd, Stevenage SG1 2FX, UK
3 shared publications - Jeannine Hess
Department of Chemistry, King's College London, Britannia House, 7 Trinity Street, 12, London, U.K., SE1 1DB
3 shared publications - Jonathan Bailey
Biological Inorganic Chemistry Laboratory, Francis Crick Institute, 1 Midland 10 Road, London, U.K., NW1 1AT
3 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Wiley in Angewandte Chemie
- Vol. 138 (38)
Proteome‐Wide Target Identification Using Reactive Metallo‐Scaffolds ( r ‐mS): A Platform for Metallodrug Discovery
Metal complexes offer unique opportunities as scaffolds in chemical biology and drug discovery, with tunable geometries, modular coordination environments, and structural features not readily accessible with organic molecules. Here, we introduce reactive metallo‐scaffolds ( r ‐mS ) as a class of metal complexes designed to map ligandable cysteines across the mammalian proteome. These covalent warhead‐bearing metal complexes use the metal centre and ligand architecture to modulate cysteine engagement, with cysteine labelling occurring through the electrophilic chloroacetamide warhead. Using chemoproteomics, we profiled a focused r ‐mS series in HEK293T lysate, identifying novel cysteine ligandability and demonstrating how metal identity, arene substituents and overall molecular topography govern cysteine reactivity and proteome‐wide targeting. Among the series screened, r ‐mS‐2 emerged as the most productive scaffold, which engaged cysteine 119 within the functionally relevant SAM‐binding domain of PRMT1. This interaction was validated by intact protein LC‐MS and was determined to functionally inhibit the activity of PRMT1. Structural modelling and docking provided insights into the molecular basis of binding, which implied π‐stacking and electrostatic complementarity in driving covalent engagement. Together, these results position reactive metallo‐scaffolds ( r ‐mS ) as a versatile platform for proteome‐wide covalent ligand discovery and the rational development of next‐generation metallodrugs.
- 10 July 2026
- Published by Wiley in Angewandte Chemie
- Vol. 138 (38)
Open AccessProteome‐Wide Target Identification Using Reactive Metallo‐Scaffolds ( r ‐mS): A Platform for Metallodrug Discovery
Metal complexes offer unique opportunities as scaffolds in chemical biology and drug discovery, with tunable geometries, modular coordination environments, and structural features not readily accessible with organic molecules. Here, we introduce reactive metallo‐scaffolds ( r ‐mS ) as a class of metal complexes designed to map ligandable cysteines across the mammalian proteome. These covalent warhead‐bearing metal complexes use the metal centre and ligand architecture to modulate cysteine engagement, with cysteine labelling occurring through the electrophilic chloroacetamide warhead. Using chemoproteomics, we profiled a focused r ‐mS series in HEK293T lysate, identifying novel cysteine ligandability and demonstrating how metal identity, arene substituents and overall molecular topography govern cysteine reactivity and proteome‐wide targeting. Among the series screened, r ‐mS‐2 emerged as the most productive scaffold, which engaged cysteine 119 within the functionally relevant SAM‐binding domain of PRMT1. This interaction was validated by intact protein LC‐MS and was determined to functionally inhibit the activity of PRMT1. Structural modelling and docking provided insights into the molecular basis of binding, which implied π‐stacking and electrostatic complementarity in driving covalent engagement. Together, these results position reactive metallo‐scaffolds ( r ‐mS ) as a versatile platform for proteome‐wide covalent ligand discovery and the rational development of next‐generation metallodrugs.
- Open Access
- 10 July 2026
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (38) , e8867549
Proteome‐Wide Target Identification Using Reactive Metallo‐Scaffolds ( r ‐mS): A Platform for Metallodrug Discovery
Metal complexes offer unique opportunities as scaffolds in chemical biology and drug discovery, with tunable geometries, modular coordination environments, and structural features not readily accessible with organic molecules. Here, we introduce reactive metallo‐scaffolds ( r ‐mS ) as a class of metal complexes designed to map ligandable cysteines across the mammalian proteome. These covalent warhead‐bearing metal complexes use the metal centre and ligand architecture to modulate cysteine engagement, with cysteine labelling occurring through the electrophilic chloroacetamide warhead. Using chemoproteomics, we profiled a focused r ‐mS series in HEK293T lysate, identifying novel cysteine ligandability and demonstrating how metal identity, arene substituents and overall molecular topography govern cysteine reactivity and proteome‐wide targeting. Among the series screened, r ‐mS‐2 emerged as the most productive scaffold, which engaged cysteine 119 within the functionally relevant SAM‐binding domain of PRMT1. This interaction was validated by intact protein LC‐MS and was determined to functionally inhibit the activity of PRMT1. Structural modelling and docking provided insights into the molecular basis of binding, which implied π‐stacking and electrostatic complementarity in driving covalent engagement. Together, these results position reactive metallo‐scaffolds ( r ‐mS ) as a versatile platform for proteome‐wide covalent ligand discovery and the rational development of next‐generation metallodrugs.
- 10 July 2026
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (38) , e8867549
Open AccessProteome‐Wide Target Identification Using Reactive Metallo‐Scaffolds ( r ‐mS): A Platform for Metallodrug Discovery
Metal complexes offer unique opportunities as scaffolds in chemical biology and drug discovery, with tunable geometries, modular coordination environments, and structural features not readily accessible with organic molecules. Here, we introduce reactive metallo‐scaffolds ( r ‐mS ) as a class of metal complexes designed to map ligandable cysteines across the mammalian proteome. These covalent warhead‐bearing metal complexes use the metal centre and ligand architecture to modulate cysteine engagement, with cysteine labelling occurring through the electrophilic chloroacetamide warhead. Using chemoproteomics, we profiled a focused r ‐mS series in HEK293T lysate, identifying novel cysteine ligandability and demonstrating how metal identity, arene substituents and overall molecular topography govern cysteine reactivity and proteome‐wide targeting. Among the series screened, r ‐mS‐2 emerged as the most productive scaffold, which engaged cysteine 119 within the functionally relevant SAM‐binding domain of PRMT1. This interaction was validated by intact protein LC‐MS and was determined to functionally inhibit the activity of PRMT1. Structural modelling and docking provided insights into the molecular basis of binding, which implied π‐stacking and electrostatic complementarity in driving covalent engagement. Together, these results position reactive metallo‐scaffolds ( r ‐mS ) as a versatile platform for proteome‐wide covalent ligand discovery and the rational development of next‐generation metallodrugs.
- Open Access
- 22 September 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Proteome-Wide Target Identification Using Reactive Metallo-Scaffolds (r-mS): A Platform for Metallodrug Discovery
Metal complexes offer unique opportunities as scaffolds in chemical biology and drug discovery, with tuneable geometry, modular coordination environments, and structural features not readily accessible with organic molecules. Here, we introduce reactive metallo-scaffolds (r-mS) - a new class of covalent warhead-containing metal complexes - designed to map ligandable cysteines across the mammalian proteome. Using chemoproteomics, we profiled a focused r-mS series in HEK293T lysate, identifying novel cysteine ligandability and demonstrating how metal identity, arene substituents and overall molecular topography govern cysteine reactivity and proteome-wide targeting. Among the series screened, r-mS-2 emerged as the most productive scaffold, which engaged cysteine 119 within the functionally relevant SAM binding domain of PRMT1. This interaction was validated via intact protein LC-MS and was determined to functionally inhibit the activity of PRMT1. Structural modelling and docking provided insights into the molecular basis of binding, which implied π-stacking and electrostatic complementarity in driving covalent engagement. Together, these results position reactive metallo-scaffolds as a versatile platform for proteome-wide covalent ligand discovery and the rational development of next-generation metallodrugs.
- 22 September 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessProteome-Wide Target Identification Using Reactive Metallo-Scaffolds (r-mS): A Platform for Metallodrug Discovery
Metal complexes offer unique opportunities as scaffolds in chemical biology and drug discovery, with tuneable geometry, modular coordination environments, and structural features not readily accessible with organic molecules. Here, we introduce reactive metallo-scaffolds (r-mS) - a new class of covalent warhead-containing metal complexes - designed to map ligandable cysteines across the mammalian proteome. Using chemoproteomics, we profiled a focused r-mS series in HEK293T lysate, identifying novel cysteine ligandability and demonstrating how metal identity, arene substituents and overall molecular topography govern cysteine reactivity and proteome-wide targeting. Among the series screened, r-mS-2 emerged as the most productive scaffold, which engaged cysteine 119 within the functionally relevant SAM binding domain of PRMT1. This interaction was validated via intact protein LC-MS and was determined to functionally inhibit the activity of PRMT1. Structural modelling and docking provided insights into the molecular basis of binding, which implied π-stacking and electrostatic complementarity in driving covalent engagement. Together, these results position reactive metallo-scaffolds as a versatile platform for proteome-wide covalent ligand discovery and the rational development of next-generation metallodrugs.